Rapamycin Potentiates TGFb Tumor Suppressor Function
雷帕霉素增强 TGFb 肿瘤抑制功能
基本信息
- 批准号:7225278
- 负责人:
- 金额:$ 24.56万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2003
- 资助国家:美国
- 起止时间:2003-07-22 至 2009-04-30
- 项目状态:已结题
- 来源:
- 关键词:Antineoplastic AgentsBindingBiological ModelsCell Cycle ArrestCell Cycle RegulationCell LineCell ProliferationClinical TrialsCyclin-Dependent KinasesDissociationE2F transcription factorsE2F1 geneEpithelial CellsGrowthHumanHuman Mammary CarcinomaMalignant Epithelial CellMalignant NeoplasmsMammary glandMediatingPharmaceutical PreparationsSignal TransductionSirolimusSmad ProteinsSmad proteinTestingThinkingTransforming Growth Factor betaTumor Suppressor Proteinscyclin-dependent kinase inhibitor 1Bin vivoinsightmalignant breast neoplasmp27 Cell Cycle Proteinp27 Enzyme Inhibitortumortumor growth
项目摘要
DESCRIPTION (provided by applicant): TGFbeta is a potent endogenous tumor suppressor and TGFbeta-induced growth arrest is abrogated in almost all human cancers. Strikingly, the Smad proteins thought to mediate TGFa-induced growth arrest are present and functional in most human mammary carcinomas. These observations suggest that in human breast cancer TGFa signaling is not inactivated per se, but that TGFbeta signaling becomes uncoupled from cell cycle regulation. We have discovered that rapamycin, an anti-cancer drug currently in clinical trials, cooperates with TGFa to induce growth arrest of normal mammary epithelial cells, and restores TGFbeta-induced cell cycle arrest in Myc, Ras, and E2F1 transformed epithelial cells. Rapamycin also restores TGFbeta-induced growth arrest in several human carcinoma cell lines. Rapamycin cooperates with TGFbetaa to inhibit cell proliferation, which results from inactivation of the cyclin-dependent kinase Cdk2. Inhibition of Cdk2 is associated with increased binding to the cyclin dependent kinase inhibitor p27. We hypothesize that rapamycin functions with TGFbeta to inhibit the proliferation of human mammary carcinoma cells by cooperatively inhibiting Cdk2 activity through increased association with p27, and through the dissociation of the E2F transcription factor from Cdk2. We further hypothesize that rapamycin cooperates with TGFbeta present in vivo to inhibit tumor growth. These hypotheses will be tested in the following Specific Aims: 1) Determine the mechanisms by which TGFbeta + rapamycin treatment induces growth arrest of no transformed mammary epithelial cells and human mammary carcinoma cells, 2) Determine the mechanisms by which TGFbeta and rapamycin regulate p27 function, and 3) Examine the interaction between TGFbeta and rapamycin anti-tumor activities in vivo. The proposed studies will employ breast cancer as a model system, but will have important implications for a wide array of tumor types. The results of these studies will yield important insights into the synergistic growth inhibitory mechanisms of TGFbeta and rapamycin, a potent endogenous tumor suppressor, and a drug currently in clinical trials against breast cancer, respectively.
描述(由申请人提供):TGF β是一种有效的内源性肿瘤抑制因子,TGF β诱导的生长停滞在几乎所有人类癌症中都被消除。引人注目的是,被认为介导TGF α诱导的生长停滞的Smad蛋白在大多数人乳腺癌中存在并起作用。这些观察结果表明,在人类乳腺癌中,TGF α信号传导本身并不失活,但TGF β信号传导与细胞周期调控脱钩。我们已经发现,雷帕霉素,一种目前在临床试验中的抗癌药物,与TGF α合作诱导正常乳腺上皮细胞的生长停滞,并恢复TGF β诱导的Myc,Ras和E2F1转化上皮细胞的细胞周期停滞。雷帕霉素还恢复了几种人类癌细胞系中TGF β诱导的生长停滞。雷帕霉素与TGF β a协同抑制细胞增殖,这是由于细胞周期蛋白依赖性激酶Cdk2失活所致。Cdk2的抑制与细胞周期蛋白依赖性激酶抑制剂p27的结合增加有关。我们假设雷帕霉素与TGF β共同作用,通过增加与p27的结合,以及通过E2F转录因子与Cdk2的解离,协同抑制Cdk2的活性,从而抑制人乳腺癌细胞的增殖。我们进一步假设雷帕霉素与体内存在的TGF β合作抑制肿瘤生长。这些假设将在以下特定目的中进行检验:1)确定TGF β +雷帕霉素处理诱导未转化的乳腺上皮细胞和人乳腺癌细胞生长停滞的机制,2)确定TGF β和雷帕霉素调节p27功能的机制,和3)检查体内TGF β和雷帕霉素抗肿瘤活性之间的相互作用。拟议的研究将采用乳腺癌作为模型系统,但将对广泛的肿瘤类型产生重要影响。这些研究的结果将产生重要的见解TGF β和雷帕霉素,一种有效的内源性肿瘤抑制剂,和目前在临床试验中对乳腺癌,分别协同生长抑制机制。
项目成果
期刊论文数量(8)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Transforming growth factor-beta induces Cdk2 relocalization to the cytoplasm coincident with dephosphorylation of retinoblastoma tumor suppressor protein.
- DOI:10.1186/bcr762
- 发表时间:2004
- 期刊:
- 影响因子:0
- 作者:Brown KA;Roberts RL;Arteaga CL;Law BK
- 通讯作者:Law BK
Rapamycin disrupts cyclin/cyclin-dependent kinase/p21/proliferating cell nuclear antigen complexes and cyclin D1 reverses rapamycin action by stabilizing these complexes.
- DOI:10.1158/0008-5472.can-05-1672
- 发表时间:2006-01-15
- 期刊:
- 影响因子:11.2
- 作者:Law, M;Forrester, E;Law, B
- 通讯作者:Law, B
An in vivo model of epithelial to mesenchymal transition reveals a mitogenic switch.
- DOI:10.1016/j.canlet.2012.08.013
- 发表时间:2012-12-30
- 期刊:
- 影响因子:9.7
- 作者:Jahn, Stephan C.;Law, Mary E.;Corsino, Patrick E.;Parker, Nicole N.;Pham, Kien;Davis, Bradley J.;Lu, Jianrong;Law, Brian K.
- 通讯作者:Law, Brian K.
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Brian K. Law其他文献
Frameless Stereotactic Navigation in Transsphenoidal Surgery: Comparison with Fluoroscopy
经蝶手术中的无框架立体定向导航:与透视检查的比较
- DOI:
10.1159/000076660 - 发表时间:
2004 - 期刊:
- 影响因子:1.7
- 作者:
I. McCutcheon;Ryan S. Kitagawa;Paula F. Demasi;Brian K. Law;K. Friend - 通讯作者:
K. Friend
Brian K. Law的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Brian K. Law', 18)}}的其他基金
HER1-3 and Death Receptor protein folding as therapeutic vulnerabilities
HER1-3 和死亡受体蛋白折叠作为治疗漏洞
- 批准号:
10721930 - 财政年份:2023
- 资助金额:
$ 24.56万 - 项目类别:
Regulation of Death Receptor 5 folding and apoptotic signaling by AGR2
AGR2 对死亡受体 5 折叠和细胞凋亡信号的调节
- 批准号:
10042651 - 财政年份:2020
- 资助金额:
$ 24.56万 - 项目类别:
Rapamycin Potentiates TGFb Tumor Suppressor Function
雷帕霉素增强 TGFb 肿瘤抑制功能
- 批准号:
7090095 - 财政年份:2003
- 资助金额:
$ 24.56万 - 项目类别:
Rapamycin Potentiates TGFb Tumor Suppressor Function
雷帕霉素增强 TGFb 肿瘤抑制功能
- 批准号:
6947331 - 财政年份:2003
- 资助金额:
$ 24.56万 - 项目类别:
Rapamycin Potentiates TGFb Tumor Suppressor Function
雷帕霉素增强 TGFb 肿瘤抑制功能
- 批准号:
6678797 - 财政年份:2003
- 资助金额:
$ 24.56万 - 项目类别:
Rapamycin Potentiates TGFb Tumor Suppressor Function
雷帕霉素增强 TGFb 肿瘤抑制功能
- 批准号:
6773355 - 财政年份:2003
- 资助金额:
$ 24.56万 - 项目类别:
相似国自然基金
帽结合蛋白(cap binding protein)调控乙烯信号转导的分子机制
- 批准号:32170319
- 批准年份:2021
- 资助金额:58.00 万元
- 项目类别:面上项目
帽结合蛋白(cap binding protein)调控乙烯信号转导的分子机制
- 批准号:
- 批准年份:2021
- 资助金额:58 万元
- 项目类别:
ID1 (Inhibitor of DNA binding 1) 在口蹄疫病毒感染中作用机制的研究
- 批准号:31672538
- 批准年份:2016
- 资助金额:62.0 万元
- 项目类别:面上项目
番茄EIN3-binding F-box蛋白2超表达诱导单性结实和果实成熟异常的机制研究
- 批准号:31372080
- 批准年份:2013
- 资助金额:80.0 万元
- 项目类别:面上项目
P53 binding protein 1 调控乳腺癌进展转移及化疗敏感性的机制研究
- 批准号:81172529
- 批准年份:2011
- 资助金额:58.0 万元
- 项目类别:面上项目
DBP(Vitamin D Binding Protein)在多发性硬化中的作用和相关机制的蛋白质组学研究
- 批准号:81070952
- 批准年份:2010
- 资助金额:35.0 万元
- 项目类别:面上项目
研究EB1(End-Binding protein 1)的癌基因特性及作用机制
- 批准号:30672361
- 批准年份:2006
- 资助金额:24.0 万元
- 项目类别:面上项目
相似海外基金
Collaborative Research: NSF-BSF: How cell adhesion molecules control neuronal circuit wiring: Binding affinities, binding availability and sub-cellular localization
合作研究:NSF-BSF:细胞粘附分子如何控制神经元电路布线:结合亲和力、结合可用性和亚细胞定位
- 批准号:
2321481 - 财政年份:2024
- 资助金额:
$ 24.56万 - 项目类别:
Continuing Grant
Collaborative Research: NSF-BSF: How cell adhesion molecules control neuronal circuit wiring: Binding affinities, binding availability and sub-cellular localization
合作研究:NSF-BSF:细胞粘附分子如何控制神经元电路布线:结合亲和力、结合可用性和亚细胞定位
- 批准号:
2321480 - 财政年份:2024
- 资助金额:
$ 24.56万 - 项目类别:
Continuing Grant
Postdoctoral Fellowship: OPP-PRF: Understanding the Role of Specific Iron-binding Organic Ligands in Governing Iron Biogeochemistry in the Southern Ocean
博士后奖学金:OPP-PRF:了解特定铁结合有机配体在控制南大洋铁生物地球化学中的作用
- 批准号:
2317664 - 财政年份:2024
- 资助金额:
$ 24.56万 - 项目类别:
Standard Grant
Conformations of musk odorants and their binding to human musk receptors
麝香气味剂的构象及其与人类麝香受体的结合
- 批准号:
EP/X039420/1 - 财政年份:2024
- 资助金额:
$ 24.56万 - 项目类别:
Research Grant
NPBactID - Differential binding of peptoid functionalized nanoparticles to bacteria for identifying specific strains
NPBactID - 类肽功能化纳米粒子与细菌的差异结合,用于识别特定菌株
- 批准号:
EP/Y029542/1 - 财政年份:2024
- 资助金额:
$ 24.56万 - 项目类别:
Fellowship
Alkane transformations through binding to metals
通过与金属结合进行烷烃转化
- 批准号:
DP240103289 - 财政年份:2024
- 资助金额:
$ 24.56万 - 项目类别:
Discovery Projects
I-Corps: Translation Potential of Real-time, Ultrasensitive Electrical Transduction of Biological Binding Events for Pathogen and Disease Detection
I-Corps:生物结合事件的实时、超灵敏电转导在病原体和疾病检测中的转化潜力
- 批准号:
2419915 - 财政年份:2024
- 资助金额:
$ 24.56万 - 项目类别:
Standard Grant
CRII: OAC: Development of a modular framework for the modeling of peptide and protein binding to membranes
CRII:OAC:开发用于模拟肽和蛋白质与膜结合的模块化框架
- 批准号:
2347997 - 财政年份:2024
- 资助金额:
$ 24.56万 - 项目类别:
Standard Grant
How lipid binding proteins shape the activity of nuclear hormone receptors
脂质结合蛋白如何影响核激素受体的活性
- 批准号:
DP240103141 - 财政年份:2024
- 资助金额:
$ 24.56万 - 项目类别:
Discovery Projects
The roles of a universally conserved DNA-and RNA-binding domain in controlling MRSA virulence and antibiotic resistance
普遍保守的 DNA 和 RNA 结合域在控制 MRSA 毒力和抗生素耐药性中的作用
- 批准号:
MR/Y013131/1 - 财政年份:2024
- 资助金额:
$ 24.56万 - 项目类别:
Research Grant














{{item.name}}会员




